Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome

Pediatric Nephrology

Volumn 30, Issue 8, 2015, Pages 1367-1370

  Counsilman, Clare E ^a   Jol–van der Zijde, Cornelia M ^a   Stevens, Jasper ^c   Cransberg, Karlien ^b   Bredius, Robbert G M ^a   Sukhai, Ram N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; CYCLOSPORIN; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN G; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PROTEIN; RAMIPRIL; RITUXIMAB; TACROLIMUS; IMMUNOLOGIC FACTOR;

ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; CASE REPORT; CHILD; CHILD UROLOGY; CLINICAL DECISION MAKING; CONGENITAL NEPHROTIC SYNDROME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY BIOPSY; KIDNEY CLEARANCE; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEINURIA; SCHOOL CHILD; STEROID THERAPY; THERAPY RESISTANCE; TREATMENT REFUSAL; UREA NITROGEN BLOOD LEVEL; DRUG RESISTANCE; HALF LIFE TIME; NEPHROTIC SYNDROME;

CHILD; DRUG RESISTANCE; HALF-LIFE; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEPHROTIC SYNDROME; RITUXIMAB;

EID: 84933177403     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-015-3120-8     Document Type: Article

References (16)

1. Kessel A, Rosner I, Toubi E (2008) Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 34:74–79
2. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279
3. Liossis SN, Sfikakis PP (2008) Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127:280–285
4. Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25:461–468
5. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5:2207–2212
6. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308–1315
7. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC (2008) Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73:117–1125
8. Ng CM, Bruno R, Combs D, Davies B (2005) Population pharmacokinetics of Rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45:792–801
9. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227
10. Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ (2010) Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69:409–412
11. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:1117–1124
12. Kemper MJ, Lehnhardt A, Zawischa A, Oh J (2014) Is rituximab effective in childhood nephrotic syndrome? Yes and no. Pediatr Nephrol 29:1305–1311
13. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321–1328
14. Kari JA, El-Morshedy SM, El-Desoky S, Alshaya HO, Rahim KA, Edrees BM (2011) Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr Nephrol 26:733–737
15. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281
16. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A (2013) A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 6:1